Emcure Pharmaceuticals Limited (IN:EMCURE)
:EMCURE
Want to see IN:EMCURE full AI Analyst Report?
Top Page
Emcure Pharmaceuticals Limited
(EMCURE)
Select Model
Select Model
Rating:66Neutral
Price Target:
₹1,985.00
▲(47.55% Upside)
Action:N/A
Date:05/09/26
The score is driven mainly by improving financial performance (strong growth, better profitability, and conservative leverage) but moderated by weaker cash conversion and gross margin volatility. Technicals are modestly supportive with a positive longer-term trend but neutral momentum. Valuation is the largest drag due to a high P/E and minimal dividend yield.
Positive Factors
Revenue & Profitability Growth
Sustained FY2026 top-line expansion and mid-teens operating margins indicate the business is improving core profitability. This strengthens earnings durability, funds reinvestment (R&D, sales), and supports operating leverage over the next several quarters absent large one-offs.
Negative Factors
Weak Cash Conversion
Free cash flow materially lagging net income suggests earnings are not fully converting to cash, likely due to working capital or receivables. That constrains organic funding for capex, acquisitions or payouts and raises reliance on external financing if earnings slip.
Read all positive and negative factors
Positive Factors
Negative Factors
Revenue & Profitability Growth
Sustained FY2026 top-line expansion and mid-teens operating margins indicate the business is improving core profitability. This strengthens earnings durability, funds reinvestment (R&D, sales), and supports operating leverage over the next several quarters absent large one-offs.
Read all positive factors
Emcure Pharmaceuticals Limited (EMCURE) vs. iShares MSCI India ETF (INDA)
Market Cap
₹356.92B
Dividend Yield0.21%
Average Volume (3M)197.42K
Price to Earnings (P/E)38.6
Beta (1Y)0.80
Revenue Growth16.56%
EPS Growth34.08%
CountryIN
Employees6,731
SectorHealthcare
Sector Strength45
IndustryDrug Manufacturers - Specialty & Generic
Share Statistics
EPS (TTM)22.89
Shares Outstanding189,659,550
10 Day Avg. Volume24,274
30 Day Avg. Volume197,417
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)6.11
Price to Sales (P/S)3.29
P/FCF Ratio61.74
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
₹2,100.00Price Target Upside56.09% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)60.78
Revenue Forecast (FY)₹104.32B
Emcure Pharmaceuticals Limited Business Overview & Revenue Model
Company Description
Emcure Pharmaceuticals Limited is committed to providing high-quality, cost-effective healthcare solutions to a global market. The company boasts a diverse product lineup spanning numerous medical fields, such as women's health (gynecology), anti-...
How the Company Makes Money
Emcure primarily makes money by selling pharmaceutical products manufactured in its facilities to customers in India and abroad. Its key revenue streams typically include: (1) Domestic branded formulations: sales of prescription medicines marketed...
Emcure Pharmaceuticals Limited Financial Statement Overview
Summary
Income Statement
78
Positive
Balance Sheet
74
Positive
Cash Flow
63
Positive
| Breakdown | TTM | Mar 2025 | Mar 2025 |
|---|---|---|---|
Income Statement | |||
| Total Revenue | 42.98B | 92.04B | 78.08B |
| Gross Profit | 23.41B | 35.79B | 275.05M |
| EBITDA | 8.39B | 17.89B | 14.95B |
| Net Income | 4.32B | 9.24B | 6.81B |
Balance Sheet | |||
| Total Assets | 93.93B | 96.12B | 82.33B |
| Cash, Cash Equivalents and Short-Term Investments | 6.02B | 2.16B | 1.98B |
| Total Debt | 16.59B | 15.21B | 10.23B |
| Total Liabilities | 45.09B | 46.36B | 35.91B |
| Stockholders Equity | 47.43B | 49.50B | 44.46B |
Cash Flow | |||
| Free Cash Flow | 5.07B | 4.90B | 4.45B |
| Operating Cash Flow | 7.48B | 8.51B | 8.52B |
| Investing Cash Flow | -6.40B | -11.95B | -940.01M |
| Financing Cash Flow | 1.99B | 4.38B | -8.14B |
Emcure Pharmaceuticals Limited Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
76 Outperform | ₹283.24B | 55.88 | ― | 0.89% | 12.25% | 3.57% | |
74 Outperform | ₹360.24B | 49.60 | ― | 0.86% | 5.87% | 6.56% | |
66 Neutral | ₹356.92B | 38.55 | ― | 0.21% | 16.56% | 34.08% | |
64 Neutral | ₹204.30B | 28.25 | ― | 0.69% | 10.45% | -5.88% | |
60 Neutral | ₹202.14B | 32.14 | ― | 0.47% | 8.15% | 75.47% | |
59 Neutral | ₹209.57B | 111.87 | ― | 0.35% | 32.59% | 62.01% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
* Healthcare Sector Average
IN:EMCURE
Emcure Pharmaceuticals Limited
1,881.90
565.77
42.99%
IN:ASTRAZEN
AstraZeneca Pharma India Limited
8,382.65
-325.91
-3.74%
IN:ERIS
Eris Lifesciences Ltd
1,458.80
-151.51
-9.41%
IN:JBCHEPHARM
JB Chemicals & Pharmaceuticals Ltd.
2,243.65
517.55
29.98%
IN:LALPATHLAB
Dr. Lal PathLabs Limited
1,689.60
326.13
23.92%
IN:PFIZER
PFIZER LIMITED
4,465.70
-1,047.67
-19.00%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.